#1 Clinical Trials Search in Europe

Rintatolimod

Rintatolimod, also known as Ampligen, is a drug being studied in clinical trials for its potential to treat various conditions. This article explores the ongoing research into rintatolimod’s efficacy and safety for diseases like pancreatic cancer, post-COVID conditions, colorectal cancer, and chronic fatigue syndrome. We’ll examine how rintatolimod works to stimulate the immune system and its possible benefits when combined with other treatments.

Table of Contents

What is Rintatolimod?

Rintatolimod, also known by its brand names Ampligen and Atvogen, is an investigational drug that is being studied for its potential to treat various conditions[1]. It is a type of medication called an immunomodulator, which means it can affect how your immune system works[2]. Rintatolimod is a synthetic double-stranded RNA molecule, which is a type of genetic material similar to what’s found in some viruses[3].

How Rintatolimod Works

Rintatolimod works by stimulating your immune system. Specifically, it activates a part of your immune system called Toll-like receptor 3 (TLR-3)[3]. When TLR-3 is activated, it can trigger a cascade of events in your body that:

  • Boosts your immune response: This can help your body fight off infections or potentially recognize and attack cancer cells more effectively.
  • Increases the maturation of dendritic cells: Dendritic cells are important immune cells that help your body recognize threats and coordinate an immune response.
  • Enhances the activity of natural killer cells: These are special immune cells that can directly kill infected or cancerous cells.
  • Stimulates the production of interferons: Interferons are proteins that help your body fight viral infections and may have anti-cancer properties.
By activating these immune responses, rintatolimod may help your body combat various diseases more effectively[3][4].

Conditions Treated with Rintatolimod

Rintatolimod is being studied as a potential treatment for several conditions:

  • Pancreatic Cancer: It’s being investigated for use in patients with locally advanced or metastatic pancreatic cancer, often in combination with other treatments[1][3].
  • Triple-Negative Breast Cancer: Researchers are studying its effectiveness in metastatic triple-negative breast cancer when combined with other immunotherapy drugs[2].
  • Colorectal Cancer: It’s being tested in patients with metastatic or unresectable colorectal cancer that hasn’t responded to other treatments[4].
  • Post-COVID Condition (Long COVID): Rintatolimod is being evaluated for its potential to alleviate fatigue in people experiencing long-term effects after COVID-19 infection[5].
  • Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): It has been studied for its potential benefits in people with this complex, chronic illness[6].
  • HIV Infection: Early studies looked at rintatolimod’s potential effects on HIV, though these were primarily conducted in the past[7][8].
It’s important to note that for many of these conditions, rintatolimod is still considered experimental and is not yet approved as a standard treatment.

How Rintatolimod is Administered

Rintatolimod is typically given as an intravenous (IV) infusion, which means it’s delivered directly into your bloodstream through a vein. The specific dosage and frequency can vary depending on the condition being treated and the particular clinical trial. Some common administration patterns include:

  • Twice weekly infusions, often at doses ranging from 200mg to 400mg[1][5].
  • In some cancer studies, it may be given on specific days of a treatment cycle, such as days 1-3 of a 21-day cycle[4].
  • The duration of treatment can vary widely, from several weeks to many months, depending on the study protocol and how well the patient responds to the treatment.
Always follow your healthcare provider’s instructions exactly when receiving rintatolimod or participating in a clinical trial.

Current Clinical Trials

Rintatolimod is currently being studied in several clinical trials:

  • Pancreatic Cancer: A phase 2 study is evaluating rintatolimod in combination with standard care for locally advanced pancreatic cancer[1]. Another study is looking at combining rintatolimod with an immunotherapy drug called durvalumab for metastatic pancreatic cancer[3].
  • Triple-Negative Breast Cancer: A trial is investigating rintatolimod as part of a combination therapy for metastatic triple-negative breast cancer[2].
  • Colorectal Cancer: Researchers are studying rintatolimod in combination with pembrolizumab (another immunotherapy drug) for patients with advanced colorectal cancer[4].
  • Post-COVID Condition: A phase 2 study is assessing rintatolimod’s effectiveness in treating fatigue associated with long COVID[5].
These trials aim to determine how effective and safe rintatolimod is for these conditions. They typically measure outcomes such as how long patients live without their disease worsening (progression-free survival), overall survival rates, and how well tumors respond to the treatment.

Potential Side Effects

As with any medication, rintatolimod can potentially cause side effects. However, it’s important to note that not everyone experiences side effects, and the severity can vary from person to person. Some potential side effects that have been observed in clinical trials include:

  • Flu-like symptoms (such as fever, chills, fatigue)
  • Nausea
  • Headache
  • Changes in appetite
  • Injection site reactions
In clinical trials, researchers carefully monitor participants for any adverse effects. If you’re receiving rintatolimod as part of a clinical trial, you’ll be asked to report any symptoms or problems you experience[7][8]. Always inform your healthcare provider about any side effects you experience.

Condition Study Phase Combination Therapy Primary Outcome Measures
Pancreatic Cancer Phase 2 Standard of care chemoradiation Progression Free Survival (PFS)
Post-COVID Condition Phase 2 None (rintatolimod alone) Change in PROMIS Fatigue Score
Colorectal Cancer Phase 2a Pembrolizumab Objective Response Rate (ORR)
Chronic Fatigue Syndrome Not specified None (rintatolimod alone) Safety and efficacy
HIV Infections Phase 1 None (rintatolimod alone) Safety, antiviral effects, immune function

FAQ

  • What is rintatolimod and how does it work? Rintatolimod, also known as Ampligen, is a synthetic double-stranded RNA molecule that acts as a TLR-3 agonist. It works by stimulating the immune system, particularly by increasing dendritic cell maturation and activating natural killer cells. This immune-boosting effect is being studied for its potential to fight various diseases.
  • What conditions is rintatolimod being studied for in clinical trials? Rintatolimod is being investigated in clinical trials for several conditions, including pancreatic cancer, post-COVID conditions (especially fatigue), colorectal cancer, chronic fatigue syndrome/myalgic encephalomyelitis, and HIV infections. It's often studied in combination with other treatments to potentially enhance their effectiveness.
  • How is rintatolimod administered in clinical trials? In most clinical trials, rintatolimod is administered intravenously (IV). The dosage and frequency can vary depending on the specific study, but common regimens include twice-weekly infusions, with doses ranging from 200mg to 400mg. Some trials adjust the dose based on patient response and tolerability.
  • What are some potential side effects of rintatolimod? While specific side effects can vary between individuals and studies, common side effects observed in clinical trials include flu-like symptoms, fatigue, and injection site reactions. However, it's important to note that the full safety profile is still being evaluated in ongoing clinical trials.
  • How long do rintatolimod clinical trials typically last? The duration of rintatolimod clinical trials can vary widely depending on the condition being studied and the trial phase. Some trials last for several weeks, while others may continue for months or even up to two years. Follow-up periods after treatment completion are also common to assess long-term effects and outcomes.

Ongoing Clinical Trials on Rintatolimod

  • Study on Durvalumab and Rintatolimod for Patients with Metastatic Pancreatic Cancer

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands

  • Study on the Effects of Rintatolimod After FOLFIRINOX in Patients with Locally Advanced Pancreatic Cancer

    Not yet recruiting

    1 1
    Investigated drugs:
    The Netherlands

Glossary

  • Rintatolimod: A synthetic double-stranded RNA molecule that acts as a TLR-3 agonist, designed to stimulate the immune system. Also known by the brand name Ampligen.
  • TLR-3 agonist: A substance that activates Toll-like receptor 3, a part of the immune system that recognizes viral particles and triggers an immune response.
  • Intravenous (IV): A method of administering medication directly into a vein using a needle or tube.
  • Pancreatic ductal adenocarcinoma (PDAC): A type of cancer that starts in the ducts of the pancreas, which is a common and aggressive form of pancreatic cancer.
  • Post-COVID Condition: Also known as Long COVID, it refers to a range of symptoms that can last weeks or months after first being infected with the virus that causes COVID-19.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from the start of treatment for a disease that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Immune checkpoint inhibitor: A type of drug that blocks certain proteins made by immune system cells, such as T cells, and some cancer cells, which can help the immune system kill cancer cells.
  • Chronic Fatigue Syndrome (CFS): Also known as Myalgic Encephalomyelitis (ME), a complex disorder characterized by extreme fatigue that can't be explained by any underlying medical condition.

References

  1. https://clinicaltrials.eu/trial/study-on-the-effects-of-rintatolimod-after-folfirinox-in-patients-with-locally-advanced-pancreatic-cancer/
  2. https://clinicaltrials.gov/study/NCT03599453
  3. https://clinicaltrials.eu/trial/study-on-durvalumab-and-rintatolimod-for-patients-with-metastatic-pancreatic-cancer/
  4. https://clinicaltrials.gov/study/NCT04119830
  5. https://clinicaltrials.gov/study/NCT05592418
  6. https://clinicaltrials.gov/study/NCT00215800
  7. https://clinicaltrials.gov/study/NCT00000713
  8. https://clinicaltrials.gov/study/NCT00000735